Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering the degradation of specific transcription factors such as Ikaros and Aiolos. This results in reduced tumor cell proliferation, enhanced immune‑mediated killing of malignant cells, and inhibition of new blood‑vessel formation, collectively promoting apoptosis of abnormal plasma cells.

The dose of Lenalidomid Zentiva is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Prescribers determine the appropriate strength, frequency, and duration in accordance with current clinical guidelines and product labeling.

Lenalidomid Zentiva is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It must not be used during pregnancy, and effective contraception is required for both men and women of reproductive potential. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant.

To order Lenalidomid Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

The primary alternative within the same class is pomalidomide, which shares the immunomodulatory mechanism but differs in potency and approved indications. Compared with thalidomide, lenalidomide has a more favorable safety profile, especially regarding peripheral neuropathy, while offering stronger anti‑angiogenic and anti‑myeloma activity.

Lenalidomid Zentiva should be stored at ambient temperature below 25 °C, protected from moisture, light, and excessive heat. Keep the product in its original blister or bottle, and ensure the container is tightly closed when not in use to maintain stability throughout its shelf life.

Lenalidomid Zentiva is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water, preferably on an empty stomach or as directed by the prescriber. Dosing times and any food restrictions are determined by the treating physician based on the therapeutic plan.

The most serious risks include venous thromboembolism (blood clots), severe neutropenia or thrombocytopenia that can lead to infections or bleeding, secondary primary malignancies, and significant liver injury. Patients should be monitored regularly for signs of these events, and any sudden symptoms should be reported to a healthcare professional immediately.

Lenalidomid Zentiva is contraindicated in pregnant women and in individuals who are not using effective contraception. It should also be avoided in patients with severe renal impairment, uncontrolled infections, or known hypersensitivity to lenalidomide or any excipients in the formulation.